# EDGAR Filing Document

**Accession Number:** 0001837493
**File Stem:** 0001213900-23-008263
**Filing Date:** 2023-2
**Character Count:** 24138
**Document Hash:** f9c1a85817b485c6dda589143ccc9eda
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-008263.hdr.sgml**: 20230206

**ACCESSION NUMBER**: 0001213900-23-008263

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 24

**CONFORMED PERIOD OF REPORT**: 20230206

**FILED AS OF DATE**: 20230206

**DATE AS OF CHANGE**: 20230206

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inspira Technologies OXY B.H.N. Ltd
- **CENTRAL INDEX KEY:** 0001837493
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40303
- **FILM NUMBER:** 23588451

**BUSINESS ADDRESS:**
- **STREET 1:** HATIDHAR 2
- **STREET 2:** 11TH FLOOR
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4366504
- **BUSINESS PHONE:** 972-9-9664488

**MAIL ADDRESS:**
- **STREET 1:** HATIDHAR 2
- **STREET 2:** 11TH FLOOR
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4366504

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of: February 2023** 

**Commission File Number: 001-40303**

**Inspira Technologies Oxy B.H.N. Ltd.**

**(Translation of registrant's name into English)**

**2 Ha-Tidhar St.**

**Ra'anana 4366504, Israel**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

**<u>CONTENTS</u>**

This Report of Foreign Private Issuer on Form 6-K consists of the Registrant's corporate presentation that was posted to its website on February 6, 2023, and which is attached hereto as Exhibit 99.1.

---

| | |
|:---|:---|
| **Exhibit No.** |  |
| 99.1 | [Corporate Presentation.](ea172783ex99-1_inspiratech.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Inspira Technologies Oxy B.H.N. Ltd.** | **Inspira Technologies Oxy B.H.N. Ltd.** | **Inspira Technologies Oxy B.H.N. Ltd.** |
| Date: February 6, 2023 | By: | /s/ Dagi Ben-Noon | /s/ Dagi Ben-Noon |
|  |  | Name: | Dagi Ben-Noon |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

• \ Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 1 Investor Presentation NASDAQ: $IINN, $IINNW February 2023

![](ex99-1_002.jpg)

Forward looking - Statements \* The Inspira ART and the ART presented in this presentation are both referring to the INSPIRA ART This presentation of InspiraTM Technologies Oxy B . H . N . Ltd . ("Inspira Technologies" or the "Company") contains "forward - looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities law . Words such as "expects," "intends," "plans," "believes," "seeks," "estimates," and similar expressions or variations of such words are intended to identify forward - looking statements . For example, the Company is using forward - looking statements when it discusses its intention to revolutionize acute respiratory care, intended uses and potential benefits of its products and technology, its business model, the potential market growth in the industry, its strategy for gaining market penetration and market share, its go - to market strategy, potential strategic collaborations with third parties, its reimbursement strategy, its regulatory strategy, market potential for its products, commercialization of its products, the potential to use its products together with mechanical ventilation, the regulatory approval process of its product candidates and the potential submission of approvals with such regulators, the benefits and uses of its product candidates for intended patient populations, lines of therapy, the timing, and design, of its clinical studies and expected timing of regulatory approvals, the potential amounts that may be realized pursuant to its various distribution agreements and planned milestones for 2023 , and its future growth . The presentation also contains estimates with respect to the Company's health economics model . Forward - looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain . Such expectations, beliefs and projections are expressed in good faith . However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed or indicated by the forward - looking statements . Forward - looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward - looking statements . More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20 - F for the fiscal year ended December 31 , 2021 filed with the U . S . Securities and Exchange Commission (the "SEC"), which is available on the SEC's website, www . sec . govForward - looking statements speak only as of the date the statements are made . The Company assumes no obligation to update forward - looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward - looking information except to the extent required by applicable securities laws as well as subsequent filings with the SEC . If the Company does update one or more forward - looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward - looking statements . Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved 2 2

![](ex99-1_003.jpg)

Invasive Mechanical Ventilation (IMV) …is this your Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 3 Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 3 ON L Y CHOICE? Acute Respiratory Failure

![](ex99-1_004.jpg)

Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 4 Your right to choose between intubation and coma (IMV) or being awake & breathing spontaneously with the INSPIRA Ρ ART INSPIRA Ρ ART System \* The INSPIRA ART and the ART presented in this presentation are both referring to the INSPIRA ART. IMV = Invasive Mechanical Ventilation. To - date the INSPIRA Ρ ART System is still in development and has not been tested or used on humans and has not been cleared or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Creating a New Class of Respiratory Care

![](ex99-1_005.jpg)

Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 5 A non - invasive optical blood sensor being developed using machine learning based algorithms to measure blood parameters during extracorporeal procedures o Clinical Study in Q1 - 2023 o FDA Submission 510(k) H1 - 2024 HYLA Ρ Blood Sensor ALICE Ρ Device An extracorporeal blood circulation device designed to provide cardiac and pulmonary support o FDA Submission 510(k) H2 - 2023 o Potential Deployment H1 - 2024 To - date the HYLA Ρ and ALICE Ρ are still in development and have not been tested or used on humans and have not been cleared or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Creating Early Revenue Opportunities

![](ex99-1_006.jpg)

Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 6 Potential medical device companies to target \* Trademarks are the property of their respective owners. Non - Invasive Blood Parameter Measuring INSPIRA Ρ ART System Respiratory Support ALICE Ρ Device Life Support HYLA Ρ Blood Sensor To - date the INSPIRA Ρ ART System, HYLA Ρ and ALICE Ρ are still in development and have not been tested or used on humans and have not been cleared or approved the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Leading the Industry

![](ex99-1_007.jpg)

Based on Press Releases published by the company from 22 nd November 2022 to 23 rd January 2023. Inspira Achievements https://inspira - technologies.com/news/ Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 7

![](ex99-1_008.jpg)

A Growing Market Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved 8 8 Global Market Expected to Grow (Based on invasive mechanical ventilation market) Increase in the prevalence of respiratory diseases Growing geriatric population Respiratory comorbidities following COVID - 19 Acute Respiratory Failure Trends 1. "Respiratory Care Devices Market by Product". Report by "Research and Market", June 2020. ID: 5129035 2. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory Society, 2017.

![](ex99-1_009.jpg)

The Respiratory Gap Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved 9 9 Mechanical Ventilation in this presentation is referring to Invasive Mechanical Ventilation.

![](ex99-1_010.jpg)

1. Am J Respir Crit Care Med Vol. 196, P3 - 4, 2017. ATS Patient Education Series© 2017 American Thoracic Society 2. Diling Wu et al. Frontiers in pharmacology MINI REVIEW published: 09 May 2019. doi: 10.3389/fphar.2019.00482 3. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital - acquired and Ventilator - associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61 - e111. Invasive Intubation & Induced Coma Potential Risks & Complications • Ventilator - induced lung injury (VILI) • Ventilator - associated pneumonia (VAP) • Ventilator - induced diaphragmatic dysfunction • Muscular atrophy High Cost of Treatment • Prolonged Ventilation & ICU stay • Requires weaning process • Extended rehabilitation period • Patient re - admissions Invasive Mechanical Ventilation Puts Patients at Risk ¹ˉ³ 1 1 0 0 Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved

![](ex99-1_011.jpg)

Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved 1 1 1 1 1 1 Play Video The INSPIRA ART and the ART presented in this presentation are both referring to the INSPIRA ART. To - date the INSPIRA Ρ ART System, ALICE Ρ Device and HYLA Ρ Blood Sensor have not been tested or used on humans and have not been cleared or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.

![](ex99-1_012.jpg)

Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved 1 1 2 1 2 2 Targeted Benefits o Designed to assist the compromised lung, by oxygenating a reduced volume of blood to boost patient saturation levels within minutes o Aims for patient to be awake & spontaneously breathing o No need for intubation, induced coma and weaning o Potential to reduce risks, complications and high costs o Designed for larger patient populations in and beyond ICU settings A new class of acute respiratory care Breakthrough Augmented Respiration Technology, designed to reduce the need for Invasive Mechanical Ventilation (IMV) INSPIRA Ρ ART System - Overview Initial Target Population ~633,000 acute respiratory failure patients in the U.S. each year¹. The respiratory care market size is estimated to reach approximately $27.6 Bn by 2026 ² Etiologies: ARDS, Pneumonia, Sepsis, COPD and acute Asthma patients 1. 2. Kempker, Jordan A. MD, MSc et al. "The Epidemiology of Respiratory Failure in the United States 2002 – 2017: A Serial Cross - Sectional Study". Critical Care Explorations: June 2020 - Volume 2 - Issue 6 - p e0128 https:// www.marketsandmarkets.com/Market - Reports/respiratory - care - 368.html?gclid=CjwKCAiA_vKeBhAdEiwAFb_nrWoX - X7YUxRCJH1JpuEvdQ7AZYblJ - E - XJIaS6GeJgg3LXYEg9yxKBoCGBkQAvD_BwE The INSPIRA ART and the ART presented in this presentation are both referring to the INSPIRA ART. To - date the INSPIRA Ρ ART System, ALICE Ρ Device and HYLA Ρ Blood Sensor have not been tested or used on humans and have not been cleared or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.

![](ex99-1_013.jpg)

Annual Market Size ~1.2m applicable procedures annually: Acute Respiratory Failure (VV - ECMO), VA ECMO and Heart Surgery¹ Non - invasive blood measurement A non - invasive optical blood sensor being developed using machine learning based algorithms to measure blood parameters, intended to provide continuous blood parameter measurements in real - time during extracorporeal procedures Expected Regulatory Pathway - FDA 510(k) Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved 1 1 3 1 3 3 HYLA Ρ Blood Sensor - Overview To - date the INSPIRA Ρ ART System, ALICE Ρ Device and HYLA Ρ Blood Sensor have not been tested or used on humans and have not been cleared or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Key features (Incl. next generation) o Continuous & real - time measurements o Measurements: SO 2 , Hb, HCT, PCO 2 , PO 2 , Temperature o Potentially alerting physicians of sudden changes in a patient's key blood parameters, enabling prompt medical intervention o Potentially alerting perfusionists of sudden changes in oxygenator performance (i.e., blood clotting, gas supply failure, system function and blood recirculation) o Intuitive user - centric software and display o A stand - alone or integrated device 1. Based on internal market assumptions and calculations

![](ex99-1_014.jpg)

Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved 1 1 4 1 4 4 ALICE Ρ Device - Overview To - date the INSPIRA Ρ ART System, ALICE Ρ Device and HYLA Ρ Blood Sensor have not been tested or used on humans and have not been cleared or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Expected Regulatory Pathway - FDA 510(k) An extracorporeal blood circulation device designed to provide cardiac and pulmonary support Annual Market Size o $673m Market Size by 2026¹ o 15,000 - 20,000 Procedures (U.S.) ² o 337 Hospitals in the U.S. ³ with extracorporeal experience Key Features o Intuitive user - centric software and display o Ergonomic device configuration o Enabling in - hospital patient transfer with integrated lithium batteries provide up to 240 minutes of operating time when fully charged o Portable and light weight Next Generation - Key features o Compatible with Inspira's HYLA blood sensor o Allowing integration of additional new sensors 1. https ://w ww .emerg e nresearch.com/industry - report/extracorporeal - membrane - oxygenation - machine - market \*, Elso website. 2. ELSO Registry Dashboard. Data included patients from North America, Europe, Asia Pacific, Latin America, SWAAC 3. https ://w ww .e l so.org/Registry/SupportDocuments/CenterIDList.aspx

![](ex99-1_015.jpg)

` o HYLA, Q1 - 2023 (Data Collection Analysis) o INSPIRA ART, H2 - 2024 (First in Human) o INSPIRA ART, 2025 (Pilot Study) Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved o Strategic OEM agreements o Collaboration, Sheba Medical Center (Ranked in Top - 10) o World renowned KOLs continue to join our Scientific Advisory Board o Razor - Blade business model (System + Disposable Kits) o ~$480m in pre - conditional distribution agreements KOLs = Key Opinion Leaders. There is no guarantee as to the success of any trial. In addition, there is inherent risk and variability in the overall regulatory process. Approval or clearance by the FDA may not be granted, or the FDA may require different study parameters from those that are intended to be included in the submission. While the Company intends to execute on strategic distribution agreements, there is no guarantee any sales will occur pursuant to those existing agreements, and agreements that may be executed in the future. The pre - conditional distribution agreements are for a period of up to 7 - year and subject to completion of development, and the required regulatory approvals or clearances. Industry Endorsements Business Model Planned Clinical Studies Go - To - Market Strategy 15

![](ex99-1_016.jpg)

Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 1 6 1 6 Planned Product Milestone Timeline 16 Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved FDA Submission 510 (k) Additional Sites & Sales Order 1 st Sales Order H2 - 2023 H1 - 2024 H2 - 2024 2025 H1 - 2023 Clinical Study Start (Data Collection Analysis) Sheba Medical Center Up to 100 patients FDA Submission 510 (k) V&V Verification & Validation Testing FDA Clearance 1 st Market Penetration FDA Clearance 1 st Market Penetration 1 st Sales Order HYLA Compatible FiH (First in Human) Clinical Study may be outside of U.S.A Pilot Clinical Study m ay be outside of U.S.A or FDA IDE (Investigational Device Exemption) Cannula Patent Approval Clinical Study Results (Data Collection Analysis) V&V Verification & Validation Testing FDA Pre - Submission V&V Verification & Validation Testing Pre - clinical chronic model investigation INSPIRA ART Patent Results Pre - clinical study Timelines are subject to change. There is no guarantee as to the success of any trial or regulatory approval or clearance. In addition, there is inherent risk and variability in the overall regulatory process. Approval or clearance by the FDA may not be granted or the FDA may require different parameters from those that are intended to be included in the submissions. The estimated date/time of FDA clearance or approval may be subject to change and subject to approval or clearance of products by the FDA (Food & Drug Administration). There is no guarantee that the patents or patent families will be granted. Potentially some or all the clinical studies may be conducted outside of the U.S.A. Pilot Study refers to study that includes a small group of patients to be defined/decided by the company

![](ex99-1_017.jpg)

3 Patent Families Inspira Patent Portfolio Oxygenator Initiation System Pump Family #1. INS - 001 A Cannula Fixation Device – Granted in IL November 2022, Filed in U.S. September 2022 Family #2 INS - 002 Dual Lumen Cannula and Methods of Use – Granted January 2023 in U.S. Family # 3 INS - 003 Extracorporeal Oxygenation System for Low Flow Rates and Methods of Use – Filed in U.S. September 2022 Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 17 There is no guarantee that the patents or patent families will be granted

![](ex99-1_018.jpg)

Company $12 million $9.4 million $16 million incorporation Raised prior to IPO: Including funds from Israeli Innovation Authority Raised at initial public offering on NASDAQ Warrants exercised at $5.50 per share Feb.2018 2019 up to Q1 - 2021 Jul. 2021 Oct. 2021 $16.2 million, Cash on hand as of Sep 30, 2022 ~$0.9 million, average monthly burn - rate (Mar 31 to Sep 30, 2022) ~$37.4 million Total cash raised to - date Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved 1 1 8 8 Inspira Cash Management

![](ex99-1_019.jpg)

Prof. Benad Goldwasser, MD, MBA Chairman Multiple well - known industry exits Dagi Ben - Noon, BSc Co - Founder, Director & CEO Co - founder of Nano Dimension Nasdaq: NNMD Daniella Yeheskely - Hayon, PhD CTO Renowned Expert in the Field of Artificial Lung Development Joe Hayon, MBA Co - Founder, Director & President M&A experience & track record • Elscint Technologies • Arazim Advanced Technologies Yafit Tehila, CPA CFO & Legal Financial management experience in multiple public companies Avi Shabtay, BSc COO 25 yrs of Startup Development Experience Experienced Leadership Team 1 1 9 9 Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved Dr. Dekel Stavi, MD Medical Director Chairman of the Israel ECMO Society. Cardiac Surgeon at Sheba Medical Center

![](ex99-1_020.jpg)

Dr. Stephan Ledot Intensivist & ECMO Advisor World - renowned expert in critical care, ECMO, anesthesia and echocardiography. Fellowships in ECMO at the NHS, UK and cardiothoracic anesthesia at Harefield Hospital` Prof. Eddy Fan Intensivist & ECMO Advisor Medical director of the extracorporeal life support program at the Toronto General Hospital. Intensivist at the University Health Network/Mount Sinai Hospital Prof. Daniel Brodie Intensivist & ECMO Advisor President - elect of the Extracorporeal Life Support Organization (ELSO). Chairman of the Executive Committee of the International ECMO Network (ECMONet) 2 2 0 0 Scientific Advisory Board - Several World - Renowned KOLs Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved Dr. Yigal Kasif, MD ECMO Advisor Former Chairman of the Israel ECMO Society. Director of ECMO program at Sheba Medical Center. Surgeon, Specializing in Adult Cardiac Surgery, Heart Transplantation and Assist Devices. KOLs = Key Opinion Leaders.

![](ex99-1_021.jpg)

Scientific Advisory Board - Several World - Renowned KOLs 2 2 1 1 Copyr C ig o h p t yr© igh 2 t 01© 8 - 2 2 0 0 1 2 8 3 - 2 In 0 s 2 p 3 ir I a ns T p e i c ra hn T o e l c o h g n ie o s lo O g X ie Y s B O .H XY .N B . . L H T . D N . . , L A T ll D r . i , g A h l t l s ri r g e h s t e s rv re e s d erved KOLs = Key Opinion Leaders.

![](ex99-1_022.jpg)

US Public Relations Dave Gentry Red Chip Companies Inc. 1 - 800 - RED - CHIP (733 - 2447) or 407 - 491 - 4498 I INN@redchip.com • \ Copyright© 2018 - 2023 Inspira Technologies OXY B.H.N. LTD., All rights reserved 22 info@inspirao 2.com www. inspira - technologies.com